Austin, United States
Molecular Templates, headquartered in Austin, Texas, is a cutting-edge biopharmaceutical firm dedicated to innovating the realm of biologic therapeutics. Their focus lies in developing treatments for cancer and other severe illnesses using their proprietary biologic engineered toxin body (ETB) drug platform. This unique platform offers a novel mechanism of action distinctly different from traditional antibody drug conjugates (ADCs).
Currently, Molecular Templates has a robust pipeline of ETBs in development. Notable among these are MT-6402, MT-5111, and MT-0169, all in Phase I clinical trials targeting various types of cancer. The firm also collaborates with industry giant Bristol Myers Squibb to develop novel ETB-based therapies.
Established in 2001, Molecular Templates has continued to garner interest from investors, evidenced by the recent $9.50M Post-IPO equity investment from Santé Ventures, BB Biotech Ventures, and BVF Partners. The company's strategic partnerships and continuous innovations make it a compelling prospect for investment in the biotechnology sector.
Immunome, Inc.